Search

Displaying results 7161 - 7170 of 10000 in total
  1. Drug

    Hydrocortisone phosphate

    go.drugbank.com/drugs/DB14542
    ApprovedInvestigationalVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  2. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Hydroxyprogesterone

    go.drugbank.com/drugs/DB14570
    Investigational

    Synonyms: 17-Hydroxypregn-4-en-3,20-dione, Pregn-4-ene-3,20-dione-17-olCategories: Pregnen (4) Derivatives, Cytochrome P-450 Substrates
  4. Drug

    Prednisolone hemisuccinate

    go.drugbank.com/drugs/DB14633
    Investigational

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: Solu-Dacortin 1 g - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung oder Infusionslösung
  5. Drug

    Prezatide copper

    go.drugbank.com/drugs/DB14683
    Investigational

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair.

    Synonyms: Copper tripeptide-1
  6. Drug

    Willow bark

    go.drugbank.com/drugs/DB14691
    Approved

    Mixtures: Miller's Formula No. 1
  7. Drug

    Cycloguanil

    go.drugbank.com/drugs/DB14763
    Approved

    Cycloguanil is the active metabolite of proguanil.

    Categories: Heterocyclic Compounds, 1-Ring
  8. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub … 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-Ring
  9. Drug

    GDC-0425

    go.drugbank.com/drugs/DB14791
    Investigational

    GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    Piflufolastat F18, also called [F-18]-DCFPyL, is a urea-based radiopharmaceutical that binds to PSMA and allows for the visualization of cancerous prostate tissue. … Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in many tissues that plays a role in folate uptake and neurotransmitter release - it is expressed in the prostate at

    Categories: Heterocyclic Compounds, 1-RingSynonyms: DCFPyL F-18, [F-18] DCFPyL